VE by FcγRIIIa genotype among subjects infected within or after 12 months of participation in Vax004
| FcγRIIIa genotype . | ≤ 12 months HR (P) . | > 12 months HR (P) . |
|---|---|---|
| VV | 2.79 (.10) | 1.2 (.68) |
| FV | 0.78 (.45) | 1.07 (.77) |
| FF | 1.06 (.87) | 1.35 (.20) |
| FcγRIIIa genotype . | ≤ 12 months HR (P) . | > 12 months HR (P) . |
|---|---|---|
| VV | 2.79 (.10) | 1.2 (.68) |
| FV | 0.78 (.45) | 1.07 (.77) |
| FF | 1.06 (.87) | 1.35 (.20) |
Cox proportional hazard models include risk behavior score, race, and location. The hazard ratio estimates vaccine efficacy within each FcγRIIIa genotype (eg, VV vaccinees are compared with VV placebo recipients).
HR indicates hazard ratio; F indicates phenylalanine; FcγR, Fc receptor for IgG; V, valine; and VE, vaccine efficiency.